Korsana Biosciences launched with $175 million in venture backing to develop KRSA‑028, an amyloid‑targeting monoclonal antibody engineered to penetrate the blood‑brain barrier. Investors include Wellington Management, Sanofi Ventures and partners that financed the spinout; the company plans first‑in‑human studies in early 2027 with initial safety and proof‑of‑concept milestones targeted over the subsequent 12 months. Korsana positions its lead program alongside existing amyloid‑clearing antibodies but aims to differentiate via improved brain delivery. The financing funds early clinical activity and builds a pipeline aimed at other neurodegenerative targets.